Evidence map›Paper›PMID 36225516›Full record

ArticleCureus2022

Atorvastatin as a Rare Primary Cause of Drug-Induced Angioedema: A Case Report.

Diana Voloshyna, Saman Al Barznji, Tanveer Ahamad Shaik, Afsar Rizvi, Reya Sachdev, Payal Pritwani, Faraz Saleem, Muhammad Abu Zar Ghaffari

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Losartan-induced Angioedema: A Case Report and Review of Literature.Journal of community hospital internal medicine perspectives · 2026
    Article
  3. Bradykinin Metabolism and Drug-Induced Angioedema.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 5 countries.

Diana VoloshynaCollege of Medicine, University of Michigan, Ann Arbor, USA.
Saman Al BarznjiInternal Medicine, University of Sulaymaniyah, Sulaymaniyah, IRQ.
Tanveer Ahamad ShaikCardiovascular Medicine, University of Louisville School of Medicine, Louisville, USA.
Afsar RizviGeneral Practice, Swan Practice, Manchester, GBR.
Reya SachdevMedicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK.
Payal PritwaniInternal Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK.
Faraz SaleemInternal Medicine, Akhtar Saeed Medical and Dental College, Lahore, PAK.
Muhammad Abu Zar GhaffariInternal Medicine, Akhtar Saeed Medical and Dental College, Lahore, PAK.
CMH Lahore Medical College and Institute of Dentistry · PKIraq Virtual Science Library · IQUniversity of Louisville · USKarachi Medical and Dental College · PKSree Gokulam Medical College and Research Foundation · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In patients with hyperlipidemia and cardiovascular disease, statin remains the primary medication for risk reduction. Statins are primarily associated with adverse outcomes like myoglobinuria and deranged liver function tests (LFTs). Angioedema is a life-threatening reaction characterized by mucosal and submucosal swelling. It is rarely known for its association with statins. However, we present a rare case of a 59-year-old man presenting with recurrent angioedema of the face and tongue after starting on 40mg of atorvastatin, within one week of the treatment. He had no previous history of hypersensitivity and rash. He denied any food or medication allergy in the past. The Naranjo scale probability and the abrupt nature of these episodes upon starting statin and completely resolving after discontinuing the drug made statin-induced angioedema the primary diagnosis in this case.

Indexed as

angioedemaatorvastatin induced angioedemacardiovascularcardiovascular preventiondrug-induced angioedemanaranjo scalerare adverse effectstatin

Identifiers

PMID36225516
PMCPMC9533254
OpenAlexW4294613052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.